Login to Your Account



BergenBio in $9M Series A For First-in-Class Cancer Drug

By Cormac Sheridan
BioWorld International Correspondent

Wednesday, January 11, 2012
BergenBio AS raised $8.8 million in a Series A funding round to bring a first-in-class AXL kinase inhibitor into the clinic for oncology indications.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription